Valuation : NovoCure Limited

Market Cap 2.09B 1.8B 1.69B 1.55B 2.89B 197B 2.9B 19.98B 7.75B 101B 7.84B 7.67B 326B P/E 2026 *
-14.3x
P/E 2027 * -22x
Enterprise Value 1.98B 1.71B 1.6B 1.47B 2.74B 187B 2.75B 18.97B 7.35B 96.05B 7.45B 7.29B 310B EV / Sales 2026 *
2.73x
EV / Sales 2027 * 2.33x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 day+1.70%
1 week+0.67%
Current month+1.64%
1 month+10.26%
3 months-0.28%
6 months+33.68%
Current year+38.75%
1 week 17.29
Extreme 17.29
18.59
1 month 15.58
Extreme 15.58
18.61
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
143.69
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 2025-11-30
Director of Finance/CFO 52 2024-12-31
Chief Tech/Sci/R&D Officer - 2023-01-16
Director TitleAgeSince
Director/Board Member 59 2011-12-31
Chairman 63 2008-12-31
Director/Board Member 64 2011-08-04
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Chief Executive Officer

1,905 0.0016%
6/30/26 Free

Head of Human Resources

1,905 0.0016%
6/30/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+1.70%+0.67%+49.75%-19.52% 2.09B
+0.32%+0.15%+15.18%+21.98% 12.69B
-0.98%-2.26%+15.69%+25.94% 6.88B
-2.33%+15.85% - - 6.54B
-2.41%-7.59%+30.36%+20.60% 5.99B
+3.02%+1.31%-17.27%+53.59% 5.21B
+0.51%-1.90%-29.86%-22.51% 3.83B
-2.02%-3.00%-7.32%+130.04% 1.72B
+2.63%-1.57%+53.11%-14.27% 1.64B
-1.26%+1.19%-3.23%+18.55% 1.38B
Average -0.08%+0.53%+11.82%+23.82% 4.8B
Weighted average by Cap. -0.25%+1.05%+10.91%+23.16%

Financials

2026 *2027 *
Net sales 726M 625M 587M 537M 1B 68.58B 1.01B 6.94B 2.69B 35.15B 2.73B 2.67B 113B 805M 693M 651M 595M 1.11B 76.04B 1.12B 7.7B 2.98B 38.97B 3.02B 2.96B 126B
Net income -142M -122M -115M -105M -197M -13.42B -197M -1.36B -527M -6.88B -533M -522M -22.19B -84.78M -73.01M -68.59M -62.7M -117M -8.01B -118M -811M -314M -4.11B -318M -311M -13.24B
Net Debt -105M -90.84M -85.33M -78.01M -146M -9.97B -146M -1.01B -391M -5.11B -396M -387M -16.48B -210M -181M -170M -155M -290M -19.84B -291M -2.01B -778M -10.17B -788M -771M -32.79B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
26-09-04 US$17.94 +1.70% 732,170
26-09-03 US$17.64 -1.07% 613,412
26-09-02 US$17.83 +2.59% 1,324,037
26-09-01 US$17.38 -1.53% 800,360
26-08-31 US$17.65 -0.95% 914,820
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
17.94USD
Average target price
27.14USD
Spread / Average Target
+51.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock